Latest news with #UX143
Business Upturn
3 days ago
- Business
- Business Upturn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.
NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ('Ultragenyx' or the 'Company') (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Ultragenyx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On July 9, 2025, Ultragenyx and its development partner Mereo BioPharma Group plc issued a press release 'announc[ing] that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis[.]' Following a Data Monitoring Committee meeting, the two companies advised that the final analysis would occur 'around the end of the year.' On this news, Ultragenyx's stock price fell $10.41 per share, or 25.11%, to close at $31.04 per share on July 10, 2025. The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See . Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle PeytonPomerantz LLP [email protected] 646-581-9980 ext. 7980
Business Wire
18-07-2025
- Business
- Business Wire
RARE Investors Have Opportunity to Join Ultragenyx Pharmaceutical Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ('Ultragenyx' or 'the Company') (NASDAQ: RARE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Ultragenyx and development partner Mereo BioPharma Group plc issued a press release on July 9, 2025, to announce that the 'randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis." The Company disclosed that this final analysis would occur "around the end of the year." Based on this news, shares of Ultragenyx fell by more than 25.1% on the next day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
